<DOC>
	<DOCNO>NCT02562612</DOCNO>
	<brief_summary>The purpose study collect response pharmacokinetic data oral administration cocktail combination 4 drug develop indication metastatic breast cancer .</brief_summary>
	<brief_title>Study SM-88 Advanced Cancers</brief_title>
	<detailed_description>The primary objective clinical trial assess response rate PFS previously treat breast cancer patient . Additional objective include pharmacokinetics multiple ascend dos SM-88 , cocktail combination 4 drug develop indication metastatic breast cancer . Secondary objective study include assessment safety tolerability ascend dos orally administer SM-88 . Additional response data also collect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Healthy adult subject , 18 70 year age , willing able give write informed consent . 2 . Subjects must willing able comply clinical trial procedure timeline outline Time Events Table . 3 . Subjects continuous nonsmoker use nicotinecontaining product least three month prior dose Day 1 . 4 . Body mass index ( BMI ) 20 29 . 5 . As outlined section 5.1.1.1 , subject childbearing potential must agree use approve method contraception duration clinical trial three month dose IMP . 6 . Must able swallow retain oral medication . 7 . Subjects must willing discontinue use vitamins herbal supplement seven day prior IMP dose resume use supplement PK sample collect 168h/Day 8 . 1 . Prior medical history illness injury , opinion principal investigator ( PI ) , may confound result clinical trial pose additional risk subject participation clinical trial . 2 . Current historic drug alcohol abuse . 3 . Unwillingness discontinue alcohol intake 24 hour prior IMP dose collection PK sample 168h/Day 8 . 4 . Subjects history lactose intolerance . 5 . Concurrent use know history hypersensitivity component SM 88 . 6 . Clinically significant abnormal laboratory test result screen and/or baseline visit determine PI . 7 . Participation another clinical trial within 30 day prior screen . 8 . Surgery within 90 day prior dose determine PI clinically relevant . 9 . Subjects must consider medically healthy clinically significant medical history . 10 . Subjects take concomitant medication . Subjects must willing discontinue use vitamins herbal supplement seven day prior dose date clinical trial remain supplement last PK sample obtain ( 168h/Day 8 ) . 11 . Positive urine drug screening . 12 . Positive result screen human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>